Drug profile · INN
quinidine polygalacturonate
CARDIOQUIN
quinidine polygalacturonate (CARDIOQUIN) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.
Drug details — quinidine polygalacturonate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
quinidine polygalacturonate (CARDIOQUIN) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel alpha subunit blocker
Primary target: Sodium channel alpha subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is quinidine polygalacturonate?
quinidine polygalacturonate (CARDIOQUIN) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for quinidine polygalacturonate?
CARDIOQUIN is a marketed brand name for quinidine polygalacturonate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of quinidine polygalacturonate?
quinidine polygalacturonate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.